Fig. 6.
Fig. 6. (A) EMSAs of CD10/NEP region I in the presence or absence of oligonucleotides from known CCAAT binding factors. A double-stranded region I oligonucleotide was 32P-labeled and incubated with 5 μg Nalm-6 nuclear protein in the absence (−) (lane 1) or presence of 100-fold molar excess of the indicated unlabeled double-stranded oligonucleotides: CBF/NF-Y, lane 2; C/EBP, lane 3; CTF/NFI, lane 4; self, lane 5. (B) EMSAs of CD10/NEP region I in the presence or absence of a CBF/NF-Y oligonucleotide or antibody. 32P-labeled double-stranded region I oligonucleotide was also incubated with Nalm-6 nuclear protein in the absence (−) (lane 6) or presence of anti–CBF-A [NF-Y] antibody (lane 7) or anti-OCT1 antibody (lane 8), or with FHTE56 nuclear protein in the absence (−) (lane 9) or presence of unlabeled self-oligonucleotide probe (lane 10), unlabeled CBF/NF-Y oligonucleotide probe (lane 11), anti–CBF-A [NF-Y] antibody (lane 12), or anti-Oct1 antibody (lane 13). Upper arrow indicates supershifted bands and lower arrow indicates major shifted bands in the absence of specific antibodies. (C) Electrophoretic mobility of region I/nuclear protein complexes from lymphoid and epithelial cells. Region I/lymphoid nuclear protein complexes (Nalm-6 [lane 14] and Raji [lane 16]) migrate slightly faster than region I/epithelial nuclear protein complexes (FHTE56 [lane 15] and Cal-1 [lane 17]).

(A) EMSAs of CD10/NEP region I in the presence or absence of oligonucleotides from known CCAAT binding factors. A double-stranded region I oligonucleotide was 32P-labeled and incubated with 5 μg Nalm-6 nuclear protein in the absence (−) (lane 1) or presence of 100-fold molar excess of the indicated unlabeled double-stranded oligonucleotides: CBF/NF-Y, lane 2; C/EBP, lane 3; CTF/NFI, lane 4; self, lane 5. (B) EMSAs of CD10/NEP region I in the presence or absence of a CBF/NF-Y oligonucleotide or antibody. 32P-labeled double-stranded region I oligonucleotide was also incubated with Nalm-6 nuclear protein in the absence (−) (lane 6) or presence of anti–CBF-A [NF-Y] antibody (lane 7) or anti-OCT1 antibody (lane 8), or with FHTE56 nuclear protein in the absence (−) (lane 9) or presence of unlabeled self-oligonucleotide probe (lane 10), unlabeled CBF/NF-Y oligonucleotide probe (lane 11), anti–CBF-A [NF-Y] antibody (lane 12), or anti-Oct1 antibody (lane 13). Upper arrow indicates supershifted bands and lower arrow indicates major shifted bands in the absence of specific antibodies. (C) Electrophoretic mobility of region I/nuclear protein complexes from lymphoid and epithelial cells. Region I/lymphoid nuclear protein complexes (Nalm-6 [lane 14] and Raji [lane 16]) migrate slightly faster than region I/epithelial nuclear protein complexes (FHTE56 [lane 15] and Cal-1 [lane 17]).

Close Modal

or Create an Account

Close Modal
Close Modal